ECHO-204: Preliminary Results of Phase I/II Trial of Epacadostat + Nivolumab in Advanced Solid Tumors

June 2-6, 2017; Chicago, Illinois
Novel combination of IDO1 inhibitor and immune checkpoint inhibitor proves active in select solid tumors.
Format: Microsoft PowerPoint (.ppt)
File Size: 878 KB
Released: June 9, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Final analysis from KEYNOTE-177 of first-line pembrolizumab vs chemotherapy in patients with MSI-H/dMMR metastatic CRC from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 17, 2021

Download these expert-selected slides covering current recommendations on evaluating and treating patients for NTRK fusion-positive cancer, from Clinical Care Options (CCO).

George D. Demetri, MD Alexander Drilon, MD Theodore Laetsch, MD Released: June 16, 2021

Download these expert-selected slides on testing for TRK fusions in your patients with cancer, from Clinical Care Options (CCO).

George D. Demetri, MD Released: June 11, 2021

Download these expert-selected slides on slides on treating patients with NTRK-positive tumors with TRK inhibitors, from Clinical Care Options (CCO).

Alexander Drilon, MD Released: June 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue